Brentuximab Vedotin Wins China Approval as First-Line Therapy for CD30-Positive PTCL
Start here
Takeda's antibody-drug conjugate brentuximab vedotin has been approved in China as a first-line treatment for CD30-positive peripheral T-cell lymphoma, becoming the first and only approved targeted therapy for this indication. The decision rests on 5-year follow-up data from the phase 3 ECHELON-2 trial, in which more than 96% of patients experienced tumor shrinkage or complete disappearance of their tumors. The approval gives Chinese patients with this T-cell lymphoma subtype access to a targeted first-line option for the first time. What remains open is how the therapy will be taken up in clinical practice across China and whether broader access questions, such as reimbursement and patient availability, will follow.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickBrentuximab Vedotin Approved in China as First-Line Therapy for CD30-Positive PTCL
Takeda announced that its ADC drug brentuximab vedotin has been approved in China as first-line treatment for CD30-positive peripheral T-cell lymphoma (PTCL), making it the first and only approved targeted therapy for this indication. The approval is based on 5-year follow-up data from the phase 3 ECHELON-2 trial, which showed tumor shrinkage or complete disappearance in more than 96% of patients.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 12:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.